Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 461-465

  Pope, Arthur J ^a   Karuppiah, Kanchana ^a   Cardounel, Arturo J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ADMA; DDAH; Endothelial dysfunction; Endothelium; eNOS; Methylarginine; Methylation; NOS; PRMT

Indexed keywords

ARGININE; CITRULLINE; DIMETHYLAMINE; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROTEIN ARGININE METHYLTRANSFERASE;

AMINO ACID METABOLISM; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METHYLATION; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC VASCULAR RESISTANCE; VASCULAR ENDOTHELIUM;

AMIDOHYDROLASES; ANIMALS; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN-ARGININE N-METHYLTRANSFERASES;

EID: 70350059137     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.016     Document Type: Review

References (35)

1. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 8 (2003) 1455-1459
2. Cardounel A.J., Cui H., Samouilov A., Johnson W., Kearns P., Tsai A.L., et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282 2 (2007) 879-887
3. Garcia R.G., Perez M., Maas R., Schwedhelm E., Boger R.H., and Lopez-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 122 2 (2007) 176-178
4. Jacobi J., Maas R., Cordasic N., Koch K., Schmieder R.E., Boger R.H., et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 294 2 (2008) H1058-H1066
5. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13 2 (2007) 198-203
6. Maas R., Dentz L., Schwedhelm E., Thoms W., Kuss O., Hiltmeyer N., et al. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 35 8 (2007) 1876-1881
7. Maas R., Quitzau K., Schwedhelm E., Spieker L., Rafflenbeul W., Steenpass A., et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis 191 1 (2007) 211-219
8. Schulze F., Lenzen H., Hanefeld C., Bartling A., Osterziel K.J., Goudeva L., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 152 3 (2006) 493 e491-8
9. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 6 (2004) 1023-1030
10. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43 3 (1999) 542-548
11. Bedford M.T., and Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 18 3 (2005) 263-272
12. Boulanger M.C., Liang C., Russell R.S., Lin R., Bedford M.T., Wainberg M.A., et al. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol 79 1 (2005) 124-131
13. Konrad L., Scheiber J.A., Bergmann M., Eickelberg O., and Hofmann R. Identification of a new human Smad6 splice variant. Andrologia 40 6 (2008) 358-363
14. Reddy S.T., Wadleigh D.J., and Herschman H.R. Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J Biol Chem 275 5 (2000) 3107-3113
15. Schwedhelm E., Maas R., Tan-Andresen J., Schulze F., Riederer U., and Boger R.H. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B: Analyt Technol Biomed Life Sci 851 1-2 (2007) 211-219
16. Tang J., Frankel A., Cook R.J., Kim S., Paik W.K., Williams K.R., et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 275 11 (2000) 7723-7730
17. Thompson P.R., and Fast W. Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock?. ACS Chem Biol 1 7 (2006) 433-441
18. Wang Y., Wysocka J., Sayegh J., Lee Y.H., Perlin J.R., Leonelli L., et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306 5694 (2004) 279-283
19. Zakrzewicz D., and Eickelberg O. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med 9 (2009) 5
20. Leiper J., Murray-Rust J., McDonald N., and Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99 21 (2002) 13527-13532
21. Leiper J.M., Santa Maria J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343 Pt 1 (1999) 209-214
22. Smith C.L., Birdsey G.M., Anthony S., Arrigoni F.I., Leiper J.M., and Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308 4 (2003) 984-989
23. Stuhlinger M.C., Conci E., Haubner B.J., Stocker E.M., Schwaighofer J., Cooke J.P., et al. Asymmetric dimethyl l-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res 75 2 (2007) 417-425
24. Tanaka M., Sydow K., Gunawan F., Jacobi J., Tsao P.S., Robbins R.C., et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112 11 (2005) 1549-1556
25. Tran C.T., Leiper J.M., and Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4 4 (2003) 33-40
26. Hong L., and Fast W. Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-l-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. J Biol Chem 282 48 (2007) 34684-34692
27. Forbes S.P., Druhan L.J., Guzman J.E., Parinandi N., Zhang L., Green-Church K.B., et al. Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation. Biochemistry 47 6 (2008) 1819-1826
28. Ogawa T., Kimoto M., and Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine:glyoxylate aminotransferase 2. J Biol Chem 265 34 (1990) 20938-20945
29. Boger G.I., Rudolph T.K., Maas R., Schwedhelm E., Dumbadze E., Bierend A., et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: effect of combination with oral l-arginine. J Am Coll Cardiol 49 23 (2007) 2274-2282
30. Boger R.H., Bode-Boger S.M., Sydow K., Heistad D.D., and Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 6 (2000) 1557-1564
31. Zoccali C., Maas R., Cutrupi S., Pizzini P., Finocchiaro P., Cambareri F., et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 22 3 (2007) 801-806
32. Vallance P., and Leiper J. Asymmetric dimethylarginine and kidney disease-marker or mediator?. J Am Soc Nephrol 16 8 (2005) 2254-2256
33. Maas R., Schulze F., Baumert J., Lowel H., Hamraz K., Schwedhelm E., et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 53 4 (2007) 693-701
34. Jacobi J., Sydow K., von Degenfeld G., Zhang Y., Dayoub H., Wang B., et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111 11 (2005) 1431-1438
35. Wang D., Gill P.S., Chabrashvili T., Onozato M.L., Raggio J., Mendonca M., et al. Isoform-specific regulation by N(G) N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 101 6 (2007) 627-635